M. U. Muckenthaler, S. Rivella, M. W. Hentze, and B. Galy, A Red Carpet for Iron Metabolism, Cell, vol.665, issue.3, pp.344-61, 2017.

P. Paananen, M. O. Arola, T. T. Pelliniemi, T. T. Salmi, and P. M. Lahteenmaki, Evaluation of the effects of 667 different transfusion trigger levels during the treatment of childhood acute lymphoblastic leukemia, J 668 Pediatr Hematol Oncol, vol.31, issue.10, pp.745-754, 2009.

J. Eng and J. D. Fish, Insidious iron burden in pediatric patients with acute lymphoblastic leukemia

, Pediatr Blood Cancer, vol.56, issue.3, pp.368-71, 2011.

B. J. Trottier, L. J. Burns, T. E. Defor, S. Cooley, and N. S. Majhail, Association of iron overload with allogeneic 672 hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver 673 iron content, Blood, vol.122, issue.9, pp.1678-84, 2013.

N. Gattermann, Iron overload in myelodysplastic syndromes (MDS), Int J Hematol, vol.107, issue.1, pp.55-675, 2018.

L. Kautz and E. Nemeth, Molecular liaisons between erythropoiesis and iron metabolism, Blood, vol.677, issue.4, pp.479-82, 2014.

S. Miura, M. Kobune, H. Horiguchi, S. Kikuchi, S. Iyama et al., EPO-R+ myelodysplastic cells 679 with ring sideroblasts produce high erythroferrone levels to reduce hepcidin expression in hepatic cells, Blood Cells Mol Dis, vol.680, pp.1-8, 2019.

T. Ganz, Hepcidin and iron regulation, 10 years later, Blood, vol.117, issue.17, pp.4425-4458, 2011.

P. Brissot and O. Loreal, Iron metabolism and related genetic diseases: A cleared land, keeping 683 mysteries, J Hepatol, vol.64, issue.2, pp.505-520, 2016.

P. Brissot, A. Pietrangelo, P. C. Adams, B. De-graaff, C. E. Mclaren et al., Nat 685 Rev Dis Primers, vol.4, p.18016, 2018.

R. Coffey and T. Ganz, Iron homeostasis: An anthropocentric perspective, J Biol Chem, vol.687, issue.31, pp.12727-12761, 2017.

L. Kautz, G. Jung, E. V. Valore, S. Rivella, E. Nemeth et al., Identification of erythroferrone as an 689 erythroid regulator of iron metabolism, Nat Genet, vol.46, issue.7, p.13, 2014.

T. Ganz, Erythropoietic regulators of iron metabolism, Free Radic Biol Med, vol.133, p.14, 2019.

F. Pilo and E. Angelucci, A storm in the niche: Iron, oxidative stress and haemopoiesis, Blood Rev, vol.692, issue.1, p.15, 2018.

A. Isidori, L. Borin, E. E. Latagliata, R. Martino, B. Palumbo et al., Iron toxicity -Its effect on the 694 bone marrow, Blood Rev, vol.695, p.16, 2018.

X. Jin, X. He, X. Cao, P. Xu, Y. Xing et al., Iron overload impairs normal hematopoietic stem and 696 progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice

, Haematologica, vol.103, issue.10, pp.1627-1661, 2018.

W. Lu, M. Zhao, S. Rajbhandary, F. Xie, X. Chai et al., Free iron catalyzes oxidative damage to 699 hematopoietic cells/mesenchymal stem cells in vitro and suppresses hematopoiesis in iron overload 700 patients, Eur J Haematol, vol.91, issue.3, pp.249-61, 2013.

X. Chai, D. Li, X. Cao, Y. Zhang, J. Mu et al., ROS-mediated iron overload injures the 702 hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice, Sci Rep, vol.703, p.19, 2015.

A. Borriello, I. Caldarelli, M. C. Speranza, S. Scianguetta, A. Tramontano et al., Iron 705 overload enhances human mesenchymal stromal cell growth and hampers matrix calcification, Biochim 706 Biophys Acta, vol.1860, issue.6, pp.1211-1234, 2016.

H. Okabe, T. Suzuki, E. Uehara, M. Ueda, T. Nagai et al., The bone marrow hematopoietic 708 microenvironment is impaired in iron-overloaded mice, Eur J Haematol, vol.93, issue.2, p.21, 2014.

Q. Zheng, Y. Zhao, J. Guo, S. Zhao, C. Fei et al., , vol.712, p.22

C. B. Laurell, Plasma iron and the transport of iron in the organism, Pharmacol Rev, vol.4, issue.4, p.23, 1952.

M. Summers, M. Worwood, and A. Jacobs, Summers MR, Jacobs A. Iron uptake and ferritin synthesis by peripheral blood leucocytes from 717 normal subjects and patients with iron deficiency and the anaemia of chronic disease, Br J Haematol, vol.28, issue.1, p.25, 1974.

M. Worwood, M. Summers, F. Miller, A. Jacobs, and J. A. Whittaker, Ferritin in blood cells from normal 720 subjects and patients with leukaemia, Br J Haematol, vol.28, issue.1, p.26, 1974.

C. Guida, S. Altamura, F. A. Klein, B. Galy, M. Boutros et al., A novel inflammatory pathway 722 mediating rapid hepcidin-independent hypoferremia, Blood, vol.125, issue.14, p.27, 2015.

R. Agoro, M. Taleb, V. Quesniaux, and C. Mura, Cell iron status influences macrophage polarization, PLoS One, vol.724, issue.5, pp.196921-725, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02126490

L. Wang, N. Azad, L. Kongkaneramit, F. Chen, Y. Lu et al., Decreased concentrations of tumor necrosis 729 factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis, J Immunol, vol.727, issue.5, pp.2581-93, 1992.

D. Haschka, V. Petzer, F. Kocher, C. Tschurtschenthaler, B. Schaefer et al., Classical and intermediate 736 monocytes scavenge non-transferrin-bound iron and damaged erythrocytes, JCI Insight, vol.8, issue.8, p.4, 2019.

J. L. Kramer, I. Baltathakis, O. S. Alcantara, and D. H. Boldt, Differentiation of functional dendritic cells and 738 macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 739 (WAF1/CIP1) and requires iron, Br J Haematol, vol.117, issue.3, p.33, 2002.

O. Olakanmi, B. Kesavalu, M. Y. Abdalla, and B. E. Britigan, Iron acquisition by Mycobacterium tuberculosis 741 residing within myeloid dendritic cells, Microb Pathog, vol.65, p.34, 2013.

N. Stojanovic, G. Jovcic, N. Basara, and V. Pavlovic-kentera, Granulopoiesis in anemic Belgrade laboratory 743 (b/b) rats, Exp Hematol, vol.18, issue.5, p.35, 1990.

N. Borregaard, Neutrophils, from marrow to microbes, Immunity, vol.33, issue.5, p.36, 2010.

E. Kolaczkowska and P. Kubes, Neutrophil recruitment and function in health and inflammation, Nat 746 Rev Immunol, vol.13, issue.3, pp.159-75, 2013.

L. Rosa, A. Cutone, M. S. Lepanto, R. Paesano, and P. Valenti, Lactoferrin: A Natural Glycoprotein Involved 748 in Iron and Inflammatory Homeostasis, Int J Mol Sci, vol.18, issue.9, 2017.

A. Delforge, P. Stryckmans, J. P. Prieels, C. Bieva, E. Ronge-collard et al., Lactoferrin: 750 its role as a regulator of human granulopoiesis?, Ann N Y Acad Sci, vol.459, p.39, 1985.

C. S. Curran and P. J. Bertics, 754 40. Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T 755 lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin 2, J Interferon Cytokine 753 Res, vol.32, issue.10, pp.450-61, 2012.

A. Sci and U. , , vol.80, pp.3494-3502, 1983.

R. M. Ned, W. Swat, and N. C. Andrews, Transferrin receptor 1 is differentially required in lymphocyte 758 development, Blood, vol.102, issue.10, pp.3711-3719, 2003.

J. C. Barton, H. W. Wiener, R. T. Acton, and R. C. Go, Total blood lymphocyte counts in hemochromatosis 760 probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA-A and -B alleles 761 and haplotypes, BMC Blood Disord, vol.5, p.5, 2005.

E. Cruz, G. Melo, R. Lacerda, S. Almeida, and G. Porto, The CD8+ T-lymphocyte profile as a modifier of iron 763 overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y 764 homozygous subjects, Blood Cells Mol Dis, vol.37, issue.1, p.44, 2006.

J. Arezes, M. Costa, I. Vieira, V. Dias, X. L. Kong et al., Non-transferrin-bound iron (NTBI) 766 uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species, PLoS 767 One, vol.8, issue.11, p.79870, 2013.

J. P. Pinto, J. Arezes, V. Dias, S. Oliveira, I. Vieira et al., Physiological implications of NTBI 769 uptake by T lymphocytes, Front Pharmacol, vol.5, p.46, 2014.

G. Porto, D. Sousa, and M. , Iron overload and immunity, World J Gastroenterol, vol.13, issue.35, p.47, 2007.

M. H. Dorner, A. Silverstone, K. Nishiya, A. De-sostoa, G. Munn et al., Ferritin synthesis by 772 human T lymphocytes, Science, vol.209, issue.4460, p.48, 1980.

T. Tanno, N. V. Bhanu, P. A. Oneal, S. H. Goh, P. Staker et al., High levels of GDF15 in thalassemia 774 suppress expression of the iron regulatory protein hepcidin, Nat Med, vol.13, issue.9, p.49, 2007.

T. Tanno, P. Porayette, O. Sripichai, S. J. Noh, C. Byrnes et al., Identification of TWSG1 776 as a second novel erythroid regulator of hepcidin expression in murine and human cells, Blood, vol.777, issue.1, p.50, 2009.

T. Tanno and J. L. Miller, Iron Loading and Overloading due to Ineffective Erythropoiesis, Adv Hematol, vol.779, p.51, 2010.

C. Camaschella and A. Nai, Ineffective erythropoiesis and regulation of iron status in iron loading 781 anaemias, Br J Haematol, vol.172, issue.4, p.52, 2016.

P. Brissot, M. B. Troadec, O. Loreal, and E. Brissot, Pathophysiology and classification of iron overload 783 diseases; update 2018, Transfus Clin Biol, vol.784, p.53, 2018.

E. Angelucci, P. Cianciulli, C. Finelli, C. Mecucci, M. T. Voso et al., Unraveling the mechanisms behind 785 iron overload and ineffective hematopoiesis in myelodysplastic syndromes, Leuk Res, vol.62, p.54, 2017.

C. Pigeon, G. Ilyin, B. Courselaud, P. Leroyer, B. Turlin et al., A new mouse liver-specific 787

, gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during 788 iron overload, J Biol Chem, vol.276, issue.11, p.55, 2001.

G. Nicolas, M. Bennoun, I. Devaux, C. Beaumont, B. Grandchamp et al., Lack of hepcidin gene 790 expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice, Proc 791 Natl Acad Sci, vol.98, p.56, 2001.

T. Ganz, Systemic iron homeostasis, Physiol Rev, vol.93, issue.4, p.57, 2013.

S. Bair, E. Spaulding, J. Parkkinen, H. M. Shulman, V. Lesnikov et al., Transplantation of 794 allogeneic T cells alters iron homeostasis in NOD/SCID mice, Blood, vol.113, issue.8, p.58, 2009.

P. Brissot, Comment je traite une hyperferritinémie, Hématologie, vol.21, p.59, 2015.

E. Brissot, B. N. Savani, and M. Mohty, Management of high ferritin in long-term survivors after 797 hematopoietic stem cell transplantation, Semin Hematol, vol.49, issue.1, p.60, 2012.

S. Bertoli, E. Paubelle, E. Berard, E. Saland, X. Thomas et al., Ferritin heavy/light chain 799 (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute 800 myeloid leukemia, Eur J Haematol, vol.102, issue.2, p.61, 2019.

Z. Defilipp, R. F. Duarte, J. A. Snowden, N. S. Majhail, D. M. Greenfield et al., Metabolic 802 Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive 803 Practice Recommendations from the CIBMTR and EBMT, Biol Blood Marrow Transplant, vol.22, issue.8, p.62, 2016.

K. M. Musallam and A. T. Taher, Iron-chelating therapy for transfusional iron overload, N Engl J Med, vol.806, issue.15, p.63, 2011.

P. Brissot and . Be, Comment j'interprète la saturation de la transferrine, Hématologie, vol.23, p.64, 2017.

Y. Gandon, D. Olivie, D. Guyader, A. C. Oberti, F. Sebille et al., Non-invasive assessment of 810 hepatic iron stores by MRI, Lancet, vol.363, issue.9406, p.65, 2004.

J. C. Wood, Estimating tissue iron burden: current status and future prospects, Br J Haematol, vol.812, issue.1, pp.15-28, 2015.

T. G. St-pierre, A. El-beshlawy, M. Elalfy, A. Jefri, A. et al., Multicenter validation of 814 spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration

, Magn Reson Med, vol.71, issue.6, pp.2215-2238, 2014.

C. Rose, P. Vandevenne, E. Bourgeois, N. Cambier, and O. Ernst, Liver iron content assessment by routine 817 and simple magnetic resonance imaging procedure in highly transfused patients, Eur J Haematol, vol.818, issue.2, p.68, 2006.

M. Regenboog, A. E. Bohte, E. M. Akkerman, J. Stoker, and C. Hollak, Iron storage in liver, bone marrow 820 and splenic Gaucheroma reflects residual disease in type 1 Gaucher disease patients on treatment, Br J 821 Haematol, vol.179, issue.4, pp.635-682, 2017.

N. Maximova, M. Gregori, G. Boz, R. Simeone, D. Zanon et al., MRI-based evaluation of 823 multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic 824 hematopoietic stem cell transplantation, Oncotarget, vol.8, issue.45, p.70, 2017.

L. Olcay, T. Hazirolan, Y. Yildirmak, E. Erdemli, Y. K. Terzi et al., Biochemical, radiologic, 826 ultrastructural, and genetic evaluation of iron overload in acute leukemia and iron-chelation therapy, J 827 Pediatr Hematol Oncol, vol.36, issue.4, p.71, 2014.

N. S. Majhail, H. M. Lazarus, and L. J. Burns, A prospective study of iron overload management in allogeneic 829 hematopoietic cell transplantation survivors, Biol Blood Marrow Transplant, vol.16, issue.6, p.72, 2010.

M. Hoeks, M. Van-der-pol, R. Middelburg, D. Evers, M. Van-kraaij et al., Bone marrow iron 831 score as an indicator for secondary iron overload in acute myeloid leukemia patients, Korean J Radiol, vol.832, issue.4, p.74, 2017.

H. Kobayashi, N. Yoshimura, S. Uemura, T. Katagiri, T. Tanaka et al., Heterogeneity of 836 intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological 837 malignancies, Eur Radiol, vol.70, issue.5, p.76, 2018.

T. Vag, K. Kentouche, I. Krumbein, J. R. Reichenbach, E. Lopatta et al., Noninvasive 842 measurement of liver iron concentration at MRI in children with acute leukemia: initial results. Pediatr 843 Radiol, vol.41, pp.980-984, 2011.

A. Moafi, M. Ziaie, M. Abedi, S. Rahgozar, N. Reisi et al., The relationship between iron 845 bone marrow stores and response to treatment in pediatric acute lymphoblastic leukemia, Medicine, vol.846, issue.44, p.8511, 2017.

P. Halonen, J. Mattila, P. Suominen, T. Ruuska, M. K. Salo et al., Iron overload in children who 848 are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters. 849 Pediatrics, vol.111, pp.91-97, 2003.

Y. Deugnier and B. Turlin, Pathology of hepatic iron overload, Semin Liver Dis, vol.31, issue.3, p.80, 2011.

P. Armand, H. T. Kim, J. Rhodes, M. M. Sainvil, C. Cutler et al., Iron overload in patients with 852 acute leukemia or MDS undergoing myeloablative stem cell transplantation, Biol Blood Marrow 853 Transplant, vol.17, issue.6, pp.852-60, 2011.

P. Brissot, M. Ropert, L. Lan, C. Loreal, and O. , Non-transferrin bound iron: A key role in iron overload 855 and iron toxicity, Biochim Biophys Acta, vol.1820, p.82, 2012.

M. B. Troadec, O. Loreal, and P. Brissot, The interaction of iron and the genome: For better and for worse
URL : https://hal.archives-ouvertes.fr/hal-01616421

, Mutat Res, vol.774, pp.25-32, 2017.

Y. Beguin, M. Aapro, H. Ludwig, L. Mizzen, and A. Osterborg, Epidemiological and nonclinical studies 859 investigating effects of iron in carcinogenesis--a critical review, Crit Rev Oncol Hematol, vol.89, issue.1, p.84, 2014.

N. Chenoufi, B. Drenou, O. Loreal, C. Pigeon, P. Brissot et al., Antiproliferative effect of 861 deferiprone on the Hep G2 cell line, Biochem Pharmacol, vol.56, issue.4, p.85, 1998.

F. Gaboriau, A. M. Leray, M. Ropert, L. Gouffier, I. Cannie et al., Effects of deferasirox and 863 deferiprone on cellular iron load in the human hepatoma cell line HepaRG, Biometals, vol.23, issue.2, p.86, 2010.

R. J. Bergeron, R. R. Streiff, and G. T. Elliott, Influence of iron on in vivo proliferation and lethality of L1210 865 cells, J Nutr, vol.115, issue.3, pp.369-74, 1985.

J. Shen, X. Sheng, Z. Chang, Q. Wu, S. Wang et al., Iron metabolism regulates p53 signaling 867 through direct heme-p53 interaction and modulation of p53 localization, stability, and function, Cell Rep, vol.868, issue.1, p.88, 2014.

A. Tarangelo, L. Magtanong, K. T. Bieging-rolett, Y. Li, J. Ye et al., p53 Suppresses Metabolic 870 Stress-Induced Ferroptosis in Cancer Cells, Cell Rep, vol.22, issue.3, p.89, 2018.

N. Zhao, A. S. Zhang, A. M. Wortham, S. Jue, M. D. Knutson et al., The Tumor Suppressor, P53, 872 Decreases the Metal Transporter, ZIP14, Nutrients, vol.9, issue.12, 2017.

M. Roth, B. Will, G. Simkin, S. Narayanagari, L. Barreyro et al., Eltrombopag inhibits the 874 proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation, Blood, vol.875, issue.2, p.91, 2012.

C. Callens, S. Coulon, J. Naudin, I. Radford-weiss, N. Boissel et al., Targeting iron 877 homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid 878 leukemia, J Exp Med, vol.207, issue.4, pp.731-50, 2010.

G. Y. Lui, Z. Kovacevic, V. Richardson, A. M. Merlot, D. S. Kalinowski et al., Targeting cancer by 880 binding iron: Dissecting cellular signaling pathways, Oncotarget, vol.6, issue.22, p.93, 2015.

J. Du, T. Wang, Y. Li, Y. Zhou, X. Wang et al., DHA inhibits proliferation and induces ferroptosis 882 of leukemia cells through autophagy dependent degradation of ferritin, Pediatr Blood Cancer, vol.883, issue.7, p.95, 2009.

R. Rodriguez-lopez, M. Donoso, M. Fernandez-cavada, L. M. Gonzalez, A. Margallo et al., 888 Diagnostic utility of HFE variants in Spanish patients: association with HLA alleles and role in susceptibility 889 to acute lymphoblastic leukemia, Gene, vol.514, issue.1, p.96, 2013.

A. E. Kennedy, K. Y. Kamdar, P. J. Lupo, M. F. Okcu, M. E. Scheurer et al., Examination of HFE 891 associations with childhood leukemia risk and extension to other iron regulatory genes, Leuk Res, vol.892, issue.9, p.97, 2014.

M. T. Dorak, A. K. Burnett, and M. Worwood, HFE gene mutations in susceptibility to childhood leukemia: 894 HuGE review, Genet Med, vol.7, issue.3, p.98, 2005.

J. M. Balagtas and G. V. Dahl, Therapeutic complications in a patient with high-risk acute lymphoblastic 896 leukemia and undiagnosed hereditary hemochromatosis. Pediatr Blood Cancer, vol.58, p.99, 2012.

A. Brunson, T. Keegan, H. Bang, A. Mahajan, S. Paulukonis et al., Increased risk of leukemia 898 among sickle cell disease patients in California, Blood, vol.130, issue.13, pp.1597-1606, 2017.

S. Alavi, A. Safari, E. Sadeghi, and S. Amiri, Hematological malignancies complicating beta-thalassemia 900 syndromes: a single center experience, Blood Res, vol.48, issue.2, pp.149-51, 2013.

N. M. Moukalled, F. A. El-rassi, S. N. Temraz, and A. T. Taher, Iron overload in patients with myelodysplastic 902 syndromes: An updated overview. Cancer, vol.124, pp.3979-3989, 2018.

R. P. Hasserjian, Myelodysplastic Syndrome Updated. Pathobiology, pp.1-7, 2018.

D. A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M. J. Borowitz et al., The 2016 revision to the 905 World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.906, issue.20, pp.2391-405, 2016.

G. F. De-souza, M. C. Barbosa, T. E. Santos, T. M. Carvalho, R. M. De-freitas et al., Increased 908 parameters of oxidative stress and its relation to transfusion iron overload in patients with 909 myelodysplastic syndromes, J Clin Pathol, vol.66, issue.11, pp.996-1004, 2013.

K. Saigo, M. Takenokuchi, Y. Hiramatsu, H. Tada, T. Hishita et al., Oxidative stress levels in 911 myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values, J Int Med 912 Res, vol.39, issue.5, pp.1941-1946, 2011.

M. Meunier, S. Ancelet, C. Lefebvre, J. Arnaud, C. Garrel et al., Reactive oxygen species levels 914 control NF-kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic 915 syndromes, Oncotarget, vol.8, issue.62, pp.105510-105534, 2017.

J. Hartmann, F. Braulke, U. Sinzig, G. Wulf, J. H. Maas et al., Iron overload impairs 917 proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes, Leuk 918 Res, vol.37, issue.3, pp.327-359, 2013.

A. C. Goncalves, E. Cortesao, B. Oliveiros, V. Alves, A. I. Espadana et al., Oxidative stress and 920 mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and 921 prognosis: A pilot study, Free Radic Res, vol.49, issue.9, pp.1081-94, 2015.

H. Ghoti, J. Amer, A. Winder, E. Rachmilewitz, and E. Fibach, Oxidative stress in red blood cells, platelets 923 and polymorphonuclear leukocytes from patients with myelodysplastic syndrome, Eur J Haematol, vol.924, issue.6, pp.463-470, 2007.

B. Novotna, Y. Bagryantseva, M. Siskova, and R. Neuwirtova, Oxidative DNA damage in bone marrow 926 cells of patients with low-risk myelodysplastic syndrome, Leuk Res, vol.33, issue.2, pp.340-343, 2009.

S. Kikuchi, M. Kobune, S. Iyama, T. Sato, K. Murase et al., Improvement of iron-mediated 928 oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment 929 with deferasirox, Free Radic Biol Med, vol.53, issue.4, pp.643-651, 2012.

Y. J. Chung, C. Robert, S. M. Gough, F. V. Rassool, and P. D. Aplan, Oxidative stress leads to increased mutation 931 frequency in a murine model of myelodysplastic syndrome, Leuk Res, vol.38, issue.1, pp.95-102, 2014.

L. Malcovati and M. Cazzola, Recent advances in the understanding of myelodysplastic syndromes with 933 ring sideroblasts, Br J Haematol, vol.174, issue.6, pp.847-58, 2016.

A. Cortelezzi, C. Cattaneo, S. Cristiani, L. Duca, B. Sarina et al., Non-transferrin-bound 935 iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?, Hematol J, vol.1, issue.3, pp.153-161, 2000.

V. Santini, D. Girelli, A. Sanna, N. Martinelli, L. Duca et al., Dyserythropoiesis evaluated 939 by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk 940 myelodysplastic syndromes, Haematologica, vol.6, issue.8, pp.497-504, 2011.

I. Ambaglio, L. Malcovati, E. Papaemmanuil, C. M. Laarakkers, D. Porta et al., 942 Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic 943 mutation of SF3B1, Haematologica, vol.98, issue.3, pp.420-423, 2013.

M. M. Patnaik and A. Tefferi, Refractory anemia with ring sideroblasts (RARS) and RARS with 945 thrombocytosis, Am J Hematol, p.946, 2019.

L. Malcovati, M. G. Porta, C. Pascutto, R. Invernizzi, M. Boni et al., Prognostic factors and 947 life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical 948 decision making, J Clin Oncol, vol.23, issue.30, pp.7594-603, 2005.

H. A. Leitch, R. Buckstein, N. Zhu, T. J. Nevill, K. Yee et al., Iron overload in myelodysplastic 950 syndromes: Evidence based guidelines from the Canadian consortium on MDS, Leuk Res, vol.74, pp.21-41, 2018.

L. F. Mantovani, F. Santos, G. F. Perini, C. Nascimento, L. P. Silva et al., Hepatic and 952 cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic 953 syndrome: A cross-sectional study, Leuk Res, vol.76, pp.53-60, 2019.

H. A. Leitch, Improving clinical outcome in patients with myelodysplastic syndrome and iron 955 overload using iron chelation therapy, Leuk Res, vol.31, issue.3, pp.7-9, 2007.

J. Neukirchen, F. Fox, A. Kundgen, K. Nachtkamp, C. Strupp et al., Improved survival in MDS 957 patients receiving iron chelation therapy -a matched pair analysis of 188 patients from the Dusseldorf 958 MDS registry, Leuk Res, vol.36, issue.8, pp.1067-70, 2012.

M. Delforge, D. Selleslag, Y. Beguin, A. Triffet, P. Mineur et al., Adequate iron chelation 960 therapy for at least six months improves survival in transfusion-dependent patients with lower risk 961 myelodysplastic syndromes, Leuk Res, vol.38, issue.5, pp.557-63, 2014.

E. Angelucci, V. Santini, D. Tucci, A. A. Quaresmini, G. Finelli et al., Deferasirox for 963 transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA 964 MDS0306 Trial), Eur J Haematol, vol.92, issue.6, pp.527-563, 2014.

A. F. Remacha, B. Arrizabalaga, A. Villegas, M. S. Duran, L. Hermosin et al., Evolution of iron 966 overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ 967 complications, Ann Hematol, vol.94, issue.5, pp.779-87, 2015.

E. Angelucci, . Lj, and P. L. Greenberg, Safety and efficacy, including event-free survival, of deferasirox 969 versus placebo in iron-overloaded patients with low-and int-1-risk myelodysplastic syndromes (MDS): 970 outcomes from the randomized, double-blind Telesto study, Abstract #234. Presented at the 2018 ASH 971 Annual Meeting, 2018.

N. Gattermann, C. Finelli, D. Porta, M. Fenaux, P. Stadler et al., Hematologic 973 responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

, Haematologica, vol.97, issue.9, pp.1364-71, 2012.

A. F. List, M. R. Baer, D. P. Steensma, A. Raza, J. Esposito et al., Deferasirox reduces 976 serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic 977 syndrome, J Clin Oncol, vol.30, issue.17, pp.2134-2143, 2012.

A. Molteni, M. Riva, A. Pellizzari, L. Borin, A. Freyrie et al., Hematological improvement 979 during iron-chelation therapy in myelodysplastic syndromes: the experience of the "Rete Ematologica 980 Lombarda, Leuk Res, vol.37, issue.10, pp.1233-1273, 2013.

S. Improta, M. R. Villa, A. Volpe, A. Lombardi, P. Stiuso et al., Transfusion-dependent low-982 risk myelodysplastic patients receiving deferasirox: Long-term follow-up, Oncol Lett, vol.6, issue.6, pp.1774-1782, 2013.

J. W. Cheong, H. J. Kim, K. H. Lee, S. S. Yoon, J. H. Lee et al., Deferasirox improves hematologic and 984 hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional 985 iron overload patients with myelodysplastic syndrome or aplastic anemia, Transfusion, vol.54, issue.6, pp.1542-986, 2014.

N. Shenoy, N. Vallumsetla, E. Rachmilewitz, A. Verma, and Y. Ginzburg, Impact of iron overload and 988 potential benefit from iron chelation in low-risk myelodysplastic syndrome, Blood, vol.124, issue.6, pp.873-81, 2014.

S. Shapira, P. Raanani, A. Samara, A. Nagler, I. Lubin et al., Deferasirox selectively induces 990 cell death in the clinically relevant population of leukemic CD34(+)CD38(-) cells through iron chelation, 991 induction of ROS, and inhibition of HIF1alpha expression, Exp Hematol, vol.70, pp.55-69, 2019.

P. Harrison, S. S. Marwah, R. T. Hughes, and D. Bareford, Non-transferrin bound iron and neutropenia after 993 cytotoxic chemotherapy, J Clin Pathol, vol.47, issue.4, pp.350-352, 1994.

F. A. Naoum, B. P. Esposito, L. P. Ruiz, M. A. Ruiz, P. Y. Tanaka et al., Assessment of labile plasma 995 iron in patients who undergo hematopoietic stem cell transplantation, Acta Haematol, vol.131, issue.4, pp.222-996, 2014.

F. A. Naoum, B. P. Esposito, and R. D. Cancado, Impact of conditioning and engraftment on iron status in 998 hematopoietic stem cell transplantation: Contribution of labile plasma iron, Hematol Oncol Stem Cell 999 Ther, vol.9, issue.4, pp.165-172, 2016.

A. Belotti, L. Duca, L. Borin, S. Realini, R. Renso et al., Non transferrin bound iron (NTBI) in 1001 acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and 1002 potential predictive role in infectious complications, Leuk Res, vol.39, issue.1, pp.88-91, 2015.

J. B. Porter, P. B. Walter, L. D. Neumayr, P. Evans, S. Bansal et al., Mechanisms of plasma 1004 non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia 1005 with sickle cell and thalassaemia patients, Br J Haematol, vol.167, issue.5, pp.692-698, 2014.

E. H. Morgan, . Ha, E. Fibach, and E. Rachmilewitz, Toxicity of iron overload and iron overload reduction in the 1009 setting of hematopoietic stem cell transplantation for hematologic malignancies, Crit Rev Oncol Hematol, vol.186, issue.2, pp.156-70, 2001.

Z. Wang, M. Jia, H. Zhao, Y. Cheng, Z. Luo et al., Prognostic impact of pretransplantation 1012 hyperferritinemia in adults undergoing allogeneic hematopoietic SCT: a meta-analysis. Bone Marrow 1013 Transplant, vol.49, pp.1339-1379, 2014.

P. Armand, H. T. Kim, J. M. Virtanen, R. K. Parkkola, M. A. Itala-remes et al., Iron overload in 1015 allogeneic hematopoietic cell transplantation outcome: a meta-analysis, Biol Blood Marrow Transplant, vol.1016, issue.8, pp.1248-51, 2014.

P. Armand, M. M. Sainvil, H. T. Kim, J. Rhodes, C. Cutler et al., Does iron overload really matter 1018 in stem cell transplantation?, Am J Hematol, vol.87, issue.6, pp.569-72, 2012.

M. Wermke, A. Schmidt, J. M. Middeke, K. Sockel, M. Von-bonin et al., MRI-based liver 1020 iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell 1021 transplantation, Clin Cancer Res, vol.18, issue.23, pp.6460-6468, 2012.

J. M. Virtanen, M. A. Itala-remes, K. J. Remes, T. Vahlberg, J. P. Saunavaara et al., Prognostic 1023 impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in 1024 allogeneic stem cell transplantation, Eur J Haematol, vol.91, issue.1, pp.85-93, 2013.

M. Wermke, J. Eckoldt, K. S. Gotze, S. A. Klein, G. Bug et al., Enhanced labile plasma iron 1026 and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic 1027 cell transplantation (ALLIVE): a prospective, multicentre, observational trial, Lancet Haematol, vol.5, issue.5, pp.201-211, 2018.

S. Sivgin, S. Baldane, G. Akyol, M. Keklik, L. Kaynar et al., The oral iron chelator deferasirox 1030 might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional 1031 iron overload, Transfus Apher Sci, vol.49, issue.2, pp.295-301, 2013.

C. Vallejo, M. Batlle, L. Vazquez, C. Solano, A. Sampol et al., Phase IV open-label study of 1033 the efficacy and safety of deferasirox after allogeneic stem cell transplantation, Haematologica, vol.1034, issue.10, pp.1632-1639, 2014.

N. Jaekel, K. Lieder, S. Albrecht, O. Leismann, K. Hubert et al., Efficacy and safety of deferasirox 1036 in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell 1037 transplantation, Bone Marrow Transplant, vol.51, issue.1, pp.89-95, 2016.

A. Kattamis, Y. Aydinok, and A. Taher, Optimising management of deferasirox therapy for patients with 1039 transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes, Eur J Haematol, vol.101, issue.3, pp.272-82, 2018.

A. T. Taher, R. Origa, S. Perrotta, A. Kouraklis, K. Belhoul et al., Influence of patient-reported 1042 outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the 1043 ECLIPSE trial: A post hoc mediation analysis, Am J Hematol, vol.94, issue.4, pp.96-105, 2019.

J. F. Tomas, I. Pinilla, M. L. Garcia-buey, A. Garcia, A. Figuera et al., Long-1045 term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 1046 patients, Bone Marrow Transplant, vol.26, issue.6, pp.649-55, 2000.

R. T. Kamble, G. B. Selby, M. Mims, M. A. Kharfan-dabaja, H. Ozer et al., Iron overload manifesting 1048 as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell 1049 transplantation, Biol Blood Marrow Transplant, vol.12, issue.5, pp.506-516, 2006.

A. K. Kew, S. Clarke, A. Ridler, S. Burrell, J. A. Edwards et al., A prospective cohort study of 1051 the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT, Bone 1052 Marrow Transplant, vol.50, issue.3, pp.457-465, 2015.

A. Busca, M. Falda, P. Manzini, D. 'antico, S. Valfre et al., Iron overload in patients 1054 receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a 1055 superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy, Blood Marrow Transplant, vol.16, issue.1, pp.115-137, 1056.